c-Myc
Os inibidores de c-Myc têm como alvo a proteína c-Myc, um fator de transcrição que desempenha um papel crucial no crescimento celular, proliferação e apoptose. c-Myc regula a expressão de numerosos genes envolvidos no ciclo celular e é frequentemente superexpresso em vários tipos de câncer, levando a uma proliferação celular descontrolada e ao crescimento tumoral. Inibir o c-Myc pode interromper esses processos, induzindo a parada do ciclo celular e a apoptose em células cancerígenas. Os inibidores de c-Myc são ferramentas importantes na pesquisa do câncer e no desenvolvimento terapêutico. Na CymitQuimica, oferecemos uma ampla gama de inibidores de c-Myc de alta qualidade para apoiar sua pesquisa em oncologia, regulação do ciclo celular e controle transcricional.
Foram encontrados 76 produtos de "c-Myc"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
c-Myc inhibitor 9
CAS:c-Myc inhibitor 9 (compound 332) with logEC50 ≥6, suppresses tumors in mice, useful for cancer research.Fórmula:C27H31N5OSCor e Forma:SolidPeso molecular:473.63VPC-70619
CAS:VPC-70619: Oral, selective N-Myc inhibitor; blocks cancer growth by hindering N-Myc-Max/DNA binding; well-absorbed.Fórmula:C16H8ClF3N4OCor e Forma:SolidPeso molecular:364.71RK-9123016
CAS:RK-9123016 is a SIRT2 inhibitor.
Fórmula:C16H18N6O3SPureza:99.65%Cor e Forma:SolidPeso molecular:374.42c-Myc inhibitor 8
CAS:c-Myc inhibitor 8 suppresses cell growth in various cancers and is used in research.Fórmula:C19H12BrClF3NO3S2Cor e Forma:SolidPeso molecular:538.79m-Se3
CAS:m-Se3 is a potent, selective inhibitor of c-MYC transcription with demonstrated capability to inhibit tumor growth and exhibit anti-cancer activity [1].Fórmula:C29H23IN2SePureza:98%Cor e Forma:SolidPeso molecular:605.37c-Myc inhibitor 4
Potent oral c-Myc inhibitor 4 reduces the proto-oncogene linked to tumor development.Fórmula:C26H33FN6O3Cor e Forma:SolidPeso molecular:496.58UM-C162
CAS:UM-C162, a benzimidazole derivative, offers protection to nematodes from Staphylococcus aureus infections. It inhibits biofilm formation without impairing bacterial viability. Additionally, UM-C162 disrupts the production of Staphylococcus aureus hemolysins, proteases, and coagulases. This compound holds potential as an antivirulence agent for managing Staphylococcus aureus infections.Fórmula:C30H25N3O4Cor e Forma:SolidPeso molecular:491.54BRD4 Inhibitor-40
CAS:BRD4 Inhibitor-40 (Compound 23) functions as an inhibitor of BRD, effectively targeting BRD4-BD1, BRD4-BD2, BRD2-BD1, and BRD2-BD2, with IC50 values of 16.1, 142.18, 29.35, and 302.35 nM, respectively. It modulates the expression of c-Myc and p21, induces cell cycle arrest in the G1 phase, and inhibits Pkd1-deficient (PN) renal cystic epithelial cells. Additionally, it prevents renal cyst formation in both Madin-Darby canine kidney and embryonic kidney cyst models, and demonstrates renal cyst inhibition activity in mouse models.Fórmula:C27H32N8OCor e Forma:SolidPeso molecular:484.596WDR5-MYC-IN-2
CAS:WDR5-MYC-IN-2 is an inhibitor of the WDR5-MYC protein-protein interaction (PPI) with an IC50 of 0.59 μM. It is utilized in research on MYC-driven cancers and in the development of other potent WDR5-MYC PPI inhibitors.Fórmula:C22H20BrClN4O4SCor e Forma:SolidPeso molecular:551.84CBP/p300-IN-2
CAS:CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc).Fórmula:C27H29F2N7O2Pureza:98%Cor e Forma:SolidPeso molecular:521.56β-catenin-IN-8
CAS:β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.Fórmula:C15H12ClN3O2SCor e Forma:SolidPeso molecular:333.79SYHA1815
CAS:SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Fórmula:C27H26ClF4N5OCor e Forma:SolidPeso molecular:547.98MY05
CAS:MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer).Fórmula:C19H11ClN4OCor e Forma:SolidPeso molecular:346.77KI-CDK9d-32
CAS:KI-CDK9d-32 is a CDK9 PROTAC degrader with a DC50 of 0.89 nM. It facilitates the ubiquitination and degradation of CDK9, inhibits the MYC pathway, and disrupts nucleolar homeostasis. KI-CDK9d-32 demonstrates anticancer activity.Fórmula:C39H45N9O4Cor e Forma:SolidPeso molecular:703.83Y-99
CAS:Y-99 is a PORCN inhibitor with an IC50 value of 155.4 nM for suppressing the Wnt/β-catenin signaling pathway. Additionally, Y-99 inhibits the expression of p-LRP6, β-catenin, and c-Myc.Fórmula:C18H17F2N5O3Cor e Forma:SolidPeso molecular:389.36JY-3-094
CAS:JY-3-094 is a selective Myc inhibitor that targets the hydrophobic domain of Myc and inhibits the formation of the Myc-Max heterodimer, with an IC50 of 33 μM, and can be used for cancer research.Fórmula:C13H8N4O5Pureza:98.72%Cor e Forma:SolidPeso molecular:300.23
